Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer
2024 · Nature Communications · 20 citations
https://doi.org/10.1038/s41467-024-50678-2
M
Merve Başar
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
30
Papers
190
Citations
8
h-index
8
i10-index
Merve Başar is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Bladder and Urothelial Cancer Treatments & Cancer Immunotherapy and Biomarkers & Urinary and Genital Oncology Studies. The author has an h-index of 8, co-authored 26 publications.
Papers by this author
worksDifferential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications
2024 · Modern Pathology · 16 citations
https://doi.org/10.1016/j.modpat.2024.100557
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma
2025 · European Urology · 13 citations
https://doi.org/10.1016/j.eururo.2025.04.008
TRANSCRIPTIONAL ANALYSIS OF BLADDER CANCER HISTOLOGIC SUBTYPES REVEALS NOVEL DRUG TARGET HETEROGENEITY
2025 · Urologic Oncology Seminars and Original Investigations · 0 citations
https://doi.org/10.1016/j.urolonc.2024.12.170
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat